Robert J. Meyer - 21 Apr 2025 Form 4 Insider Report for CHIMERIX INC

Role
Director
Signature
/s/ Michael Alrutz, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
21 Apr 2025
Net transactions value
-$300,532
Form type
4
Filing time
21 Apr 2025, 16:13:33 UTC
Previous filing
21 Jun 2024
SEC
View on sec.gov

Quoteable Key Fact

"Robert J. Meyer filed Form 4 for CHIMERIX INC on 21 Apr 2025."

Quick Takeaways

  • This page summarizes Robert J. Meyer's Form 4 filing for CHIMERIX INC.
  • 9 reported transactions and 8 derivative rows are listed below.
  • Filing timestamp: 21 Apr 2025, 16:13.

What Changed

  • Previous filing in this sequence was filed on 21 Jun 2024.
  • Current net transaction value: -$300,532.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Source Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

CMRX transaction

Common Stock

Disposed to Issuer

Transaction value
$300,532
Shares
-35,150
Change %
-100%
Price
$8.55
Shares after
0
Date
21 Apr 2025
Ownership
Direct
Footnotes
F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

CMRX transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-42,000
Change %
-100%
Price
Shares after
0
Date
21 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
42,000
Exercise price
$5.25
Footnotes
F3
CMRX transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-21,000
Change %
-100%
Price
Shares after
0
Date
21 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
21,000
Exercise price
$4.82
Footnotes
F3
CMRX transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-21,000
Change %
-100%
Price
Shares after
0
Date
21 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
21,000
Exercise price
$3.37
Footnotes
F3
CMRX transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-35,000
Change %
-100%
Price
Shares after
0
Date
21 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
35,000
Exercise price
$2.85
Footnotes
F3
CMRX transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-35,000
Change %
-100%
Price
Shares after
0
Date
21 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
35,000
Exercise price
$7.84
Footnotes
F3
CMRX transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-50,000
Change %
-100%
Price
Shares after
0
Date
21 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
50,000
Exercise price
$1.82
Footnotes
F3
CMRX transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-60,000
Change %
-100%
Price
Shares after
0
Date
21 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
60,000
Exercise price
$1.39
Footnotes
F3
CMRX transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-60,000
Change %
-100%
Price
Shares after
0
Date
21 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
60,000
Exercise price
$0.8900
Footnotes
F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Robert J. Meyer is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]
F2 [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time , each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.
F3 Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

Remarks:

The foregoing descriptions in the footnotes to this Form 4 are qualified in their entirety by reference to the terms of the Merger Agreement. In the event of any conflict between the descriptions above and the terms set forth in the Merger Agreement, the terms set forth in the Merger Agreement shall control.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .